Status:

NOT_YET_RECRUITING

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions:

Colorectal Cancer

Chemotherapy Effect

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

This study is a prospective, randomized, comparative clinical trial conducted by Wuhan Union Hospital and aim to compare the therapeutic effects of Mitomycin and Lobaplatin in the treatment of advance...

Detailed Description

Hyperthermic intraperitoneal chemotherapy (HIPEC) is traditionally used to treat peritoneal cancer combined with cytoreductive surgery (CRS). Further, there have been more than 20 years for CRS + HIPE...

Eligibility Criteria

Inclusion

  • No chemoradiotherapy or other anti-tumor therapy before clinical trial performed;
  • Aged 18-75 years;
  • Male or non-pregnant or lactating women;
  • Pathological diagnosis of colorectal adenocarcinoma;
  • Clinical diagnosis of T3 stage or above without distant metastasis and can be given radical surgery (AJCC Version 8, 2018);
  • Normal function of major organs;
  • Routine blood examinations meeting the following criteria:
  • A. HB ≥ 90 g/L; B. ANC ≥ 1.5 x 10 9 /L; C. PLT ≥ 125 × 10 9 /L;
  • Chemistry indexs meeting the following criteria:
  • A. TBIL \< 1.5ULN; B. ALT and AST \< 2.5ULN; ALB \> 30 g/L C. serum Cr ≤ 1.25 ULN or endogenous creatinine clearance \> 50 ml/min (Cockcroft-Gault formula);
  • ECOG score 0-1;

Exclusion

  • A history of other malignant tumors within 5 years;
  • Distant metastasis found during surgery;
  • Allergic to paclitaxel, lobaplatin and other related chemotherapeutic drugs;
  • Suffering from epilepsy or other mental illness, unable to control behavior;
  • Inability to tolerate surgery due to severe cardiac, pulmonary and vascular disease;
  • Pregnant or lactating women.
  • Receiving anti-cancer drug therapy from other clinical trials.

Key Trial Info

Start Date :

September 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2026

Estimated Enrollment :

201 Patients enrolled

Trial Details

Trial ID

NCT04845490

Start Date

September 1 2022

End Date

September 1 2026

Last Update

February 21 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.